Clinical-stage biopharmaceutical company developing ophthalmic treatments.
Outlook Therapeutics, Inc. is a late clinical-stage biopharmaceutical company specializing in the development and commercialization of monoclonal antibodies aimed at treating various ophthalmic conditions. The company's primary focus lies in advancing its lead product candidate, ONS-5010, an ophthalmic formulation of bevacizumab currently undergoing Phase III clinical trials. This innovative treatment is designed to address wet age-related macular degeneration and other retina diseases, potentially offering significant advancements in eye care therapies.
Outlook Therapeutics, Inc. operates through strategic collaborations and license agreements with key partners including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. These partnerships play a pivotal role in enhancing the company's research capabilities, clinical development, and commercialization effforts, ensuring robust support for its pipeline of monoclonal antibody treatments.
Founded in 2010 and headquartered in Iselin, New Jersey, Outlook Therapeutics, Inc. was previously known as Oncobiologics, Inc. before rebranding in November 2018. With a steadfast commitment to advancing ophthalmic therapies through innovation and collaboration, the company continues to expand its footprint in the biopharmaceutical industry, aiming to bring novel treatments to patients worldwide.